Hosted on MSN19d
COCP: Phase 2a Trial of CC-42344 Extended…On December 31, 2024, Cocrystal Pharma, Inc. (NASDAQ:COCP) announced that the Phase 2a clinical trial of its oral PB2 inhibitor, CC-42344, will be extended due to unexpectedly low infection rates ...
Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces favorable safety and tolerability results at dosing up to 800 mg per day ...
Shares of Cocrystal Pharma (NASDAQ:COCP) plunged 40% Tuesday after the company said it plans to extend a Phase 2a challenge study for its influenza drug candidate CC-42344 due to an unexpectedly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results